Emergent BioSolutions Inc. Investigation
Company: Emergent BioSolutions Inc.
Ticker: (NYSE) EBS
How to Check Whether You May Be Eligible in the Emergent BioSolutions Inc. Investigation
Investigation Details
Emergent BioSolutions shareholders absorbed a sharp decline after the Company reduced its FY2026 revenue guidance to $645-$675 million, down from the $720-$760 million range management had reaffirmed on its April 30, 2026 earnings call.
The timeline is specific. On February 26, 2026, Emergent issued initial FY2026 guidance of $720-$760 million in revenue and $135-$155 million in adjusted EBITDA. On that same call, Chief Financial Officer Richard S. Lindahl attributed softer NARCAN demand to the prolonged government shutdown and near-term market uncertainty, characterizing those factors as "we view as transient and not reflective of the long-term growth potential in this category." Management further stated that it expected NARCAN to maintain its leading market share, while the accompanying presentation stated that the Company had “maintained market leadership; pricing stabilized.”
On April 30, 2026, Emergent reaffirmed its FY2026 revenue guidance of $720–$760 million, leaving the forecast unchanged from February. The Company simultaneously raised its adjusted EBITDA guidance to $155–$175 million from $135–$155 million.
Roughly three months later, on August 5, 2026, Emergent reduced its FY2026 revenue guidance to $645–$675 million from $720–$760 million, a $75 million reduction at the midpoint. The Company also reduced adjusted EBITDA guidance to $130–$150 million from $155–$175 million.